



INSTITUTE FOR ANIMAL HEALTH
Director: Professor Martin W. Shirley, PhD
PIRBRIGHT LABORATORY
Ash Road,
Pirbright,
Surrey,
GU24 0NF
Intn Tel: 00 44 1483 232441
Tel: 01483 232441 Fax: 01483 232621

FMD Vaccine Matching Strain Differentiation Report

Lab Reference WRL Batch Number: WRLFMD/2009/00022

Sender Details:

[REDACTED]

Date Received: 30th April 2009

Country of Origin: Kenya

Date Reported: 18th September 2009

Results App

[REDACTED]

Official Stamp:

[REDACTED]

Date:

18/9/09

[REDACTED]

To help us improve the quality of our service, please send any suggestions or requests to the Reference Laboratory by fax (+44 (0) 1483 232621 or email: elizabeth.byrom@bbsrc.ac.uk)

Report no:	VNT				LPBE						
	VNT	O Manisa	O Bfs	O Ind R2/75	ELISA	O 4174	O BFS 1860	O K77/78	O Hkn 6/83	O 4625	O Manisa
Field Isolate:	test ref:	UV pool	VP pool	9418	test ref:	1621	1393	BVS Kenya	RJO	1439	UV2-21
O Ken 10/2009	mean	0.92	0.82	0.63	mean	0.59	0.59	0.54	0.84	0.38	>1

Interpretation of Results

In the case of Virus Neutralisation Test (VNT):

$r_1 = \geq 0.3$. Suggests that there is a close relationship between field isolate and vaccine strain. A potent vaccine containing the vaccine strain is likely to confer protection.

$r_1 = < 0.3$. Suggests that the field isolate is so different from the vaccine strain that the vaccine is unlikely to protect

In the case of Liquid Phase Blocking Elisa (LPBE):

$r_1 = 0.4-1.0$. Suggests that there is a close relationship between field isolate and vaccine strain. A potent vaccine containing the vaccine strain is likely to confer protection.

$r_1 = 0.2-0.39$, Suggests that the field isolate is antigenically related to the vaccine strain. The vaccine strain might be suitable for use if no closer match can be found provided that a potent vaccine is used and animals are preferably immunised more than once.

$r_1 = < 0.2$. Suggests that the field isolate is so different from the vaccine strain that the vaccine is unlikely to protect.